CellCentric
2 known investors
CellCentric is a clinical-stage biopharmaceutical company developing inobrodib, an oral small molecule inhibitor of the p300/CBP proteins, for the treatment of multiple myeloma and other cancers. The drug is being evaluated in clinical trials, including in combination with standard-of-care therapies for use in community care settings.
BiotechMedical Devices
Investors Β· 2
Frequently asked questions
- What does CellCentric do?
- CellCentric is a clinical-stage biopharmaceutical company developing inobrodib, an oral small molecule inhibitor of the p300/CBP proteins, for the treatment of multiple myeloma and other cancers. The drug is being evaluated in clinical trials, including in combination with standard-of-care therapies for use in community care settings.
- Who are CellCentric's investors?
- CellCentric's investors include Avego BioScience Capital, Future Planet Capital.